Outbreak of mumps associated with poor vaccine efficacy  - Oporto  Portugal 1996

Gonçalves, Guilherme; Araújo, A de; Cardoso, Maria Luı́s

doi:10.2807/esm.03.12.00101-en

Cited by 34 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 Our study confirms the findings of other researchers of the low protection conferred by the Rubini vaccine strain. The vaccine efficacy of the Rubini strain mumps vaccine on our Asian population was K55.3% whilst that in other studies [4][5][6][7][8]10,11 conducted in the European population ranged from K4 to 40%.…”

Section: Discussionmentioning

confidence: 84%

Comparative efficacy of Rubini, Jeryl–Lynn and Urabe mumps vaccine in an Asian population

Ong

Goh

et al. 2005

Journal of Infection

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 84%

Comparative efficacy of Rubini, Jeryl–Lynn and Urabe mumps vaccine in an Asian population

Ong

Goh

et al. 2005

Journal of Infection

View full text Add to dashboard Cite

“…A number of studies demonstrated substantially lower rates of seroconversion and effectiveness than the Jeryl-Lynn and Urabe AM9. Based on these data, WHO recommended that the Rubini strain vaccine NOT be used in national immunization programs [26,29]. A replacement for the Rubini with a more potent vaccine strain was progressing by the same producer however, this effort was discontinued immaturely.…”

Section: VIImentioning

confidence: 99%

Live Attenuated Measles Mumps and Rubella Vaccines: An Over View

Naim¹

2015

IJVV

View full text Add to dashboard Cite

“…Estos brotes afectaban principalmente a poblaciones susceptibles: personas no vacunadas o grupos de edad (de 15 a 23 años) que no habían tenido exposición al virus natural y tampoco estaban vacunados [14][15][16][17] . Sin embargo, ha habido también brotes en poblaciones con alta cobertura vacunal en las que se cuestionaba la efectividad de la cepa empleada para la vacunación, como en Suiza, Portugal, o España [18][19][20] . Los estudios de los brotes en estos países apuntaban hacia una escasa efectividad de la vacunación con el componente antiparotidítico de la cepa Rubini.…”

Section: Introductionunclassified

Brote de parotiditis vírica en un colegio de Bizkaia en 2006

Ortuondo¹,

Sancristóbal²,

López-Soria³

et al. 2007

Rev. Esp. Salud Publica

View full text Add to dashboard Cite

Fundamento:Recientemente se han registrado brotes de parotiditis en España y en otros países desarrollados. Los motivos barajados son la baja cobertura vacunal de las poblaciones afectadas y/o la baja efectividad de las cepas vacunales empleadas. Este trabajo describe un brote de parotiditis ocurrido en Bizkaia y valora la efectividad de las cepas vacunales y la utilidad de las pruebas diagnósticas actualmente empleadas. Métodos:Se etiquetaron como casos aquéllos con clínica compatible y vínculo epidemiológico en el periodo de estudio (febrero-mayo-2006). Se recogieron muestras de sangre para estudio de IgM e IgG y de saliva para detección de RNA y genotipo. Se averiguó el estado vacunal y la cepa empleada mediante los registros del reparto vacunal. Se realizó un análi-sis univariante de los datos y se obtuvieron riesgos relativos según las cepas vacunales empleadas.Resultados: Se detectaron 63 casos; 52 eran alumnos del mismo colegio. El 50% tenía entre 9 y 13 años. El 88,5% de los casos del colegio estaba correctamente vacunado. La sensibilidad de la IgM fue del 9% y la de la PCR del 37%. El riesgo relativo de los alumnos vacunados con una primera dosis de cepa Rubini frente a los vacunados con cepa Jeryl-Lynn fue de 3,8 (IC95% 2,27-6,49). Conclusiones:La elevada cobertura vacunal no impide el desarrollo de brotes en lugares con un alto grado de exposición. La IgM se muestra poco sensible para el diagnóstico de parotiditis. Parece necesario replantearse las estrategias vacunales y los métodos diagnósticos actuales. This study describes one outbreak of parotiditis having occurred in Bizkaia and assesses the effectiveness of the vaccine strains and the usefulness of the diagnostic tests currently used. Methods:Those cases having compatible clinical symptoms and an epidemiological link within the period under study (February-May 2006) were labeled as cases. Blood samples were taken to study IgM and IgG and saliva for genotype and RNA detection. The immunization status and the strain used were found through the vaccine distribution records. A univariate analysis was conducted on the data and relative risks calculated according to the vaccine strains used.Results: A total of 63 cases were detected, 52 being students from one school. Fifty percent were 9-13 years of age. A total of 88.5% of the cases detected at the school had been properly immunized. The IgM sensitivity was 9% , PCR sensitivity being 37%. The relative risk of those students immunized with an initial dose of Rubini strain as compared to those immunized with Jeryl-Lynn strain was 3.8 (95% CI:2.27-6.49). Conclusions:The high degree of immunization coverage does not prevent outbreaks from occurring in places having a high degree of exposure. The IgM reveals itself to be sensitive to a very small degree for the diagnosis of parotiditis. It seems necessary that the current immunization strategies and diagnostic methods be reconsidered.

show abstract

Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996

Abstract: Vaccination against mumps in Portugal began in 1987, with the introduction of the combined measles, mumps, and rubella vaccine (MMR) in the national vaccination programme (Programa Nacional de Vacinação: PNV) for both sexes at 15 months. In November 1990,

Cited by 34 publications

References 0 publications

Comparative efficacy of Rubini, Jeryl–Lynn and Urabe mumps vaccine in an Asian population

Comparative efficacy of Rubini, Jeryl–Lynn and Urabe mumps vaccine in an Asian population

Live Attenuated Measles Mumps and Rubella Vaccines: An Over View

Brote de parotiditis vírica en un colegio de Bizkaia en 2006

Contact Info

Product

Resources

About